The Phase 3 EPIC trial is a randomized, sham-controlled, double-blind study evaluating NRTX-1001 cell therapy in adults with ...
10h
Key achievements included positive Phase 3 ASPEN data for brensocatib in bronchiectasis, record-breaking ARIKAYCE revenues, and advancements in other pipeline programs such as TPIP and ARIKAYCE's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback